Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 YearContributed by: Business WireLogoImagesFigure 1: 25 mg participants who continued through Part CFigure 2: Placebo participants who continued through Part CFigure 3: Response and remission rates post open-label treatmentTagsOther HealthResearchGeneral HealthPharmaceuticalMental HealthClinical TrialsScienceBiotechnologyAlternative MedicineFDAOther ScienceHealthCompass Pathfinder Limited
